

Genomic organization and promoter characterization of human CXCR4 gene

A. Caruz^a, M. Samsom^b, J.M. Alonso^c, J. Alcami^c, F. Baleux^d, J.L. Virelizier^a,
M. Parmentier^b, F. Arenzana-Seisdedos^{a,*}

^aUnité d'Immunologie Virale. Institut Pasteur, 28 Rue Dr. Roux, 75724 Paris, France

^bIRIBHN, Université Libre de Bruxelles, B-1070 Bruxelles, Belgium

^cCentro de Investigaciones, Hospital 12 de Octubre, Madrid 28041, Spain

^dUnité de Chimie Organique. Institut Pasteur, 28 Rue Dr. Roux, 75724 Paris, France

Received 13 March 1998

Abstract CXCR4 is the receptor for the CXC chemokine SDF1 that has essential functions on embryo organogenesis, immunological functions and T lymphocyte trafficking. Recently, CXCR4 has drawn unexpected attention as it was recently identified as a co-factor required for entry of lymphotropic HIV isolates in CD4+ T lymphocytes. CXCR4 is the only SDF1 receptor identified so far. This suggests that CXCR4 expression is critical for the biological effects of SDF1. To investigate the mechanisms controlling both the constitutive and induced expression of CXCR4 receptors we have isolated and characterized the promoter region and determined the genomic structure of the human gene. The CXCR4 gene contains two exons separated by an intronic sequence. A 2.6 kb 5'-flanking region located upstream the CXCR4 open reading frame contains a TATA box and the transcription start site characteristic of a functional promoter. This region also contains putative consensus binding sequences for different transcription factors, some of them associated with the hemopoiesis and lymphocyte development.

© 1998 Federation of European Biochemical Societies.

Key words: CXC4 chemokine receptor; Promoter regulation; Transcription factor; HIV-1; Chemokine SDF1

1. Introduction

Chemokines are soluble mediators that control leukocyte migration into sites of inflammation and specific areas of lymphoid organs [1]. Activation of leukocytes is mediated by interaction of chemokines with specific receptors belonging to the family of the seven transmembrane domain, G-protein coupled receptors [2]. Chemokines carry conserved cysteines and fall into four families defined by a cysteine signature motif: CXC, CC, C or CX₃C where C is a cysteine and X any amino-acid residue [3]. Most of the chemokines belong to either CC or CXC families. Expression of CC chemokine receptors in T lymphocytes has proved to be dependent on the cell activation status and the nature of the signal used as stimulus. Thus, expression of CCR1, CCR2 or CCR5 are induced by IL2 [4,5], but are down-regulated by lectin or T cell specific activators [4,6]. Less information is available for the CXC family of receptors, although it has been reported that expression of IL8 receptors in lymphocytes is modified neither by IL2- nor CD3-mediated activation [4]. Among the

family of CXC receptors, CXCR4 has drawn unexpected attention as it was identified as a co-factor required for entry of lymphotropic HIV isolates in CD4+ T lymphocytes [7]. CXCR4 is the receptor for the CXC chemokine SDF1 [8,9] that plays a critical role in both embryonic B lymphopoiesis and organogenesis [10]. A chemoattractant for the pluripotent hematopoietic CD34+ cells [11] and a growth factor for pre- and pro-B murine lymphocytes in vitro [12], SDF1 is also known to promote the arrest on endothelium of lymphocytes rolling under flow conditions [13]. Moreover, SDF1 prevents HIV entry in host cells by both occupying [8,9] and promoting endocytosis of CXCR4 [14]. Nowadays, CXCR4 seems to be the only receptor capable of binding SDF1 selectively and permit cell signaling by this chemokine [8,15]. CXCR4 is expressed constitutively in a large number of human tissues and transformed cell lines [15]. Moreover, CXCR4 transcripts are very abundant in leukocytes [15].

To investigate the mechanisms controlling both the constitutive and induced expression of CXCR4 receptors, we have isolated and characterized the promoter region and determined the genomic structure of the human gene. The CXCR4 gene contains two exons separated by an intronic sequence. A 2.6 kb 5'-flanking region located upstream the CXCR4 open reading frame contains a TATA box and the transcription start site characteristic of a functional promoter. This region also contains putative consensus binding sequences for different transcription factors, some of them associated with hemopoiesis and lymphocyte development.

2. Materials and methods

2.1. Cells

The epithelial-like cell line HeLa was propagated in DMEM medium supplemented with 10% heat-inactivated fetal calf serum (FCS, Gibco), L-Gln and antibiotics. J.jhan cells were derived from the T lymphoblastoid cell line Jurkat and were grown in RPMI 1640 supplemented with 10% FCS. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient from healthy human donors.

2.2. DNA sequencing

Both DNA strands relative to the CXCR4 gene and the promoter region were sequenced by the dideoxy-chain termination method using the New England Biolabs cycle sequencing Kit and an automated sequencer ABI (Perkin Elmer). All sequencings were done in duplicate.

2.3. Library screening

A human BAC library from Research Genetics, Inc (2130 Memorial Parkway SW, Huntsville, AL 35801, USA) was screened according to the manufacturer's instructions by specific PCR for the CXCR4 gene. The primers used were CXCR45459: 5'-CCGAGGAAATGGGCT-

*Corresponding author. Fax: +33 1-45688941.
E-mail: farenzan@pasteur.fr

The nucleotide sequence data reported in this paper will appear in the EMBL database with the accession number AJ224869.

1 caattctgaa tctcgccttt tgcacttaat gtttcataag tatttcccca tgtcactaaa
 61 aattcttcca aataacattc acgatgtcca tatggaattt cagatgtgga tgaacccaaa
 121 tcttgtcaac tattccacta acagtggtta tttagggatg ttcagacatt tctactattha
 181 aaaaaaaatg tttccacaaa tacctttgtg gcataagttt tttatgagtgg agttactggt
Lvf1
 241 ctgaagttcc tgcgtgaatg aaaatgcttt ccagtgaggc tgtcccaagc cacattccca
 301 tccagtacaa gcgagagaca gctggtcttt tcaaatccgg agaccacaaa tttatcttga
 361 aaaaaaatg atttttgctt aatttggtag tcacacaaata gcactctcatt gttcttttaa
C-ets2
 421 ttatctgctt ccttttagta gagatcccta aaaagatctg aaaggagtct tcagataaag
 481 gaaggagctt tcttttctgt gtctacaatc aacaatatat tattatgcaa accattttgc
 541 tccgagtttt ctctctcttc cttttttgga cagatgtggg agatctcacc tttcagttt
 601 tagacatcgt gcaggagga gttttgaggt aggtgagcag ttcaggtcca ttcagataaaca
 661 tactgattct gccactacca ggctttgtga aaagcaagtc atgaaaacgc tctgaaattc
HoxD
 721 tagaccttca gtagatagga tctaccgtgt ctataaaaat atgaagatcc ttaagtttta
HoxD
 781 ttaagattc gaaaaagta aaagtgtttt tacggtttta ttttcathtt tatttcttac
 841 cgttatcggt tattataaag gatattataa aggatcacaga tgaagagata cgtaatgcaa
SP1
 901 ggcctgtgag aaggggctg gagcttccga aacctcttc agccaccacc ctccaagaac
 961 ctggagtttc tttttttttt ttttaattcta caaatgtaat attagaattg attttctctg
 1021 gccattagtg tgtgtcctaa ctctgtcgtt tctgagagtc ccatctcccg gcccgggata
PEA3 C-Jun
 1081 tcatctttcc tgtgtcagtg aaagtgcaga gtagatgaga acctttaacc accaacatta
MAZ
 1141 gggaggggct ccagacaaag ggggtaagtc atgctctgta gagaaaaggt tccctgcctc
PEA3
 1201 cgaactacct ctggaacact ccagtaaatg tttctctctt tgatatagaa aagagggatc
 1261 gtgtgtagag tgcagtcctg gcaatccctc tctcggggac catttcgggg tagggcgctc
 1321 tgggttccgt gtccgacgc acgcccctcg gtcccagcta tctccgcagc tggccacccc
SP1 SP1
 1381 gctgcccggc gcagtttctc ggccccgccc cacactcgtt cccccgccc acccagttct
 1441 gcgcccggag ggaagtggcg cgagggggaa agcactgtct gcgcccacc tgcacacctc
 1501 agccagtcct agatcgtctt aaacgtctga cccccacccc cactccgccc cgcccagttc
 1561 tccaacctaa tttctgattc gtgcccgaagc ttgtcctctg ctcaaaatcg tggagagcgc
AP2
 1621 cgagtatggg gaccgaagac ctgggttcaa gcccggcttg gaatccctgc ccatccctgg
SP1
 1681 catttcatct ctccgggctt atttgctggt ttctccgaat gcgggcttg tctggttcc
AP2
 1741 gctggatccc caacgcctag aacagtggct ggcacgcagt tctccttct ataatatcg
 1801 gactaaatgc atctctgtga tggtaatacc cacacgggtg tgtgagaatg aatgagtgat
 1861 tctgtgcaag ttcttagtga tctgttaca aaagtactgg tgcctaaatt actctataa
 1921 taaagcatac ttttaggata ataaagcact attcgcgaat tggttaccgc tattatgaaa
 1981 ttactgagca atacatatc acatctgac agtctccaaa attatgcaa atcctactct
 2041 cttctgaaag tatctcctaa ttatctgcac ctgaccctag tgatgctgtg aatgtgcaag
PEA3 C-ets2
 2101 tatagctaca tctccgaag gaaaggatct ttactccttt tacctcctga atgggctgcg
SP1 SP1
 2161 tctgctgaaa gcgcccggga atgggctggt ggaagcttgg ccctacttcc agcattgccc
C-ets2
 2221 cctactggtt gggttactcc agcaagtcac tccccttccc tgggctcag tgtctctact
 2281 gtagcattcc caggtctgga attccatcca ctttagcaag gatggacgcg ccacagagag
C-ets2
 2341 acgcttctc agcccgcgt tcccactctg cttcaggcgc atcccgcttc cctcaaaact
Lvf1
 2401 aggaaatgcc tctgggaggt cctgtccggc tccggactca ctaccgacca ccgcaaaaca
C-ets2 SP1 PU.1
 2461 gcagggtccc ctgggcttcc caagccgccc acctctccgc CCCGCCctg cgccctcctt
SP1 MAZ
 2521 cctcgcgtct gccctctcc cccaccccgc cttctccctc cccgcccag cggcgcatgc
TATA BOX
 2581 gcgcccctcg gagegtgttt tTATAAaagt ccgcccgcgg ccagaaactt cagtttgttg
Transcription start 5'UTR REGION
 2641 gctGCGGCAG CAGGTAGCAA AGTGACGCCG AGGGCCTGAG TGCTCCAGTA GCCACCGCAT
CDS 1° Exon Intron
 2701 CTGGAGAACC AGCGGTACC ATGGAGGGGA TCAGTGTAA Tccagtttca acctgctttg
 2761 tcataaatgt acaaacgttt gaacttagag cgcagccctt ctccgagcgg gcagaagcgg
 2821 ccaggacatt gagggtacc taccatcct atatatgtcg ggtgggtggg gggggagcag
 2881 gattggaatc tttttctctg tgagtcgagg agaaacgact ggaagagcgc ttcagtgcc
 2941 tgcattgtgc tccccctga gtcccggcgc gcgcccggc ttgcacgctg ttgcaaacg
 3001 taagaacatt ctgtgcacaa gtgcagagaa ggcgtgccc ctgcctcggg actcagacca
 3061 ccggtctctt ccttggggaa gcgggagatg cttggagcga gttacattgt ctgaatttag
 3121 aggcggaggg cggcgtgcct gggctgagtt cccaggagga gatgcccgcc gcttactct
 3181 cggggttaag cgcctggtga ctgttcttga cactgggtgc gtgtttgta aactctgtgc
 3241 ggccgacgga gctgtgccg tctcccagca cagtaggcag agggcgggag aggggggtgg
 3301 accacccgcg ccgatcctct gaggggatcg agtgggtgca gcagctagga gttgatccgc
 3361 ccgcccgtct tgggtttgag ggggaaacct tcccgcgctc cgaagcgtgc ctctcccca
 3421 cggcccgcag tgggtcctgc agttcagagc tttggggtcg tgcagagtg agcggagtg
 3481 tttgacctcc cctttgcac ccgcagctg ccagccctga gatttgcgt cggggatag
 3541 gagcgggtac ggggtgaggg gcggggcgg ttaaaccgca cctgggctgc caggtcgcgc

Fig. 1.

CAGGGGA-3' and CXCR45462: 5'-CATTGGGGTAGAAGCG-GTCACA-3'. The PCR mixtures contained 5 µl of DNA from the BAC library pool, 1 µl of each primer at a concentration of 500 ng/µl, 200 mM dNTPs, 1 mM of MgCl₂, 0.2 units of Taq DNA polymerase (Pharmacia), 5 µl of DMSO and water to 100 µl. Amplification was conducted for 30 cycles at 93°C 1 min, 62°C 2 min, 72°C 2.30 min, followed by a final elongation step at 72°C for 15 min. The PCR products were visualized on a 2% agarose gel stained with ethidium

bromide. This procedure led to the identification of a BAC clone (24D3) that contained the entire CXCR4 gene and adjacent sequences. The identification of a putative TATA box and consensus binding sites for transcription factors were performed using the program TESS (Transcription Element Search Software) (<http://agave.humgen.upenn.edu/teess/index.html>). Only sequences showing total homology with the canonical consensus sequence for transcription factors were considered.

```

3601 cgcgcaagac tggcagggtgc aagtggggaa accggttggc tctctccgag tccagttgtg
3661 atgtttaacc gtcggtggtt tccagaaacc ttttgaacc ctcttgctag ggagtttttg
3721 gtttctctga gggcgcgca attcaaagac gctcggcg gaggccgcca gtcgctcccc
3781 agcaccctgt gggacagagc ctggcgtgtc gccacgagc gccctgca gctgcttgc
3841 gggcggttgg cgtgggtgta gtgggcagcc gcggcgccc ggggctggac gaccggccc
3901 cccgcgtgcc caccgcctgg aggttccag ctgccacct ccggccgggt taactggatc
3961 agtgccgggg taatgggaaa ccaccggga gagtggaaa atgaaacttg gggcgaggac
4021 cacgggtgca gaccocgta ctttctccac ccaggaaaat gcccgctcc ctaactgcc
4081 aaacgcgcca agtgataaac acgaggatgg caagagacc acacaccgga ggagcgccg
4141 cttgggggag gaggtgccgt ttgttcattt tctgacact ccgcccaata taccccaagc
4201 accgaagggc cttcgtttta agaccgatt ctctttacc actacaagt gctgaagcc
4261 cagaatggtt tgtatttagg caggcgtggg aaaattaagt ttttggcct taggagaatg
4321 agtctttgca acgcccccg cctccccctc tgatcctcc tctccccct ttccccctc
4381 gggcgaaaaa cttcttaca aaagttaatc actgccctc cttagcagc ccaccccacc
4441 ccccacgccc cctgggagtg gcctcttgt gtgtatttt ttttctctc taaggaagt
4501 tttttcttc cctctagtgg gcggggcaga gggattagc aagatggtg ctttgaacc
4561 ctcagcgtct cagtgcctt ttgttctaaa caaagaattt tgtaattgt tctaccaag
4621 aaggatataa tgaagtca atgggaaaag atggggaaga aaagatggg aggaggtt
4681 taggattcta cattaattct cttgtgccct tagccacta cttcagaatt tctgaagaa
4741 agcaagcctg aattggtttt ttaaattgct ttaaaaaatt ttttaactg ggttaagt
                                     ↓ 2nd Exon
4801 tgctgaattg gaagtgaatg tccattcctt tgcctctttt gcaGATATAC ACTTCAGATA
4861 ACTACACCGA GGAATGGGC TCAGGGGACT ATGACTCCAT GAAGGAACCC TGTTCCCGT
4921 AAGAAAATGC TAATTTCAAT AAAATCTTCC TGCCACCAT CTACTCCATC ATCTCTTAA
4981 CTGGCATTGT GGGCAATGGA TTGGTCATCC TGGTCATGGG TTACAGAAG AACTGAGAA
5041 GCATGACGGA CAAGTACAGG CTGCACCTGT CAGTGGCCGA CCTCCTCTTT GTCATCACGC
5101 TTCCCTTCTG GGCAGTTGAT GCCGTGGCAA ACTGGTACTT TGGGAACCTC CTATGCAAGG
5161 CAGTCCATGT CATTACACA GTCAACCTCT ACAGCAGTGT CCTCATCTG GCCTTCATCA
5221 GTCCTGGCCG ATCCTGGCCG CCACCAACAG CCACCAACAG TCAGAGGCCA AGGAAGCTGT
5281 TGGCTGAAAA GGTGGCTAT GTTGGCGTCT GGATCCCTGC CCTCTGCTG ACTATTCCCG
5341 ACTTCATCTT TGCCAACGTC AGTGAGCAG ATGACAGATA TATCTGTGAC CGTCTTACC
5401 CCAATGACTT GTGGTGGT GTTCTCCAGT TTCAGCACAT CATGGTTGGC CTTATCCTGC
5461 CTGGTATTGT CATCTGTCC TGCTATTGCA TTATCATCTC CAAGCTGTCA CACTCCAAGG
5521 GCCACCAGAA GCGCAAGGCC CTCAAGACCA CAGTCATCCT CATCTGGCT TCTTCCGCT
5581 GTTGGCTGCC TTACTACATT GGGATCAGCA TCGACTCCTT CATCTCCTG GAAATCATCA
5641 AGCAAGGGTG TGAGTTGAG AACACTGTGC ACAAGTGGAT TTCCATCACC GAGGCCCTAG
5701 CTTTCTTCCA CTGTTGTCTG AACCCATCC TCTATGCTTT CCTTGGAGCC AAATTTAAA
5761 CCTCTGCCCA GCACGCATC ACCTCTGTGA GCAGAGGTC CAGCCTAAG ATCCTCTCA
5821 AAGAAAGCG AGGTGGACAT TCATCTGTTT CCCTGAGTC TGAGTCTTCA AGTTTCACT
5881 CCAGCTAACA CAGATGTAAA AGACTTTTT TTATACGATA AATAACTTTT TTTAAGTTA
5941 CACATTTTTC AGATATAAAA GACTGACCAA TATTGTACAG TTTTATTTC TGTGGATT
6001 TTTGCTTGT GTTCTTTAG TTTTGTGAA GTTTAATTGA CTTATTTATA TAAATTTTT
6061 TTTTTCATA TTGATGTGT TCTAGGCAGG ACCTGTGGCC AAGTCTTAG TTGCTGTATG
6121 TCTCGTGGTA GACTGTAGA AAAGGAACT GAACATTCCA GAGCGTGTAG TGAATCACGT
6181 AAAGTAGAA ATGATCCCA GCTGTTTATG CATAGATAAT CTCTCCATTC CGTGGAAACG
6241 TTTTCTCTGT TCTTAAGACG TGATTTTGCT GTAGAAGATG GCACTTATA CCAAAGCCA
6301 AAGTGTATA GAAATGCTGG TTTTTCAGT TFCAGGAGTG GGTGATTTC AGCACCTACA
6361 GTGTACAGTC TTGTATTAAG TTGTTaataa aagtacatgt taaacttact tagtgttatg
6421 tctcgatttc tgttgacatt cttttggcta gtagaagaca aaagtaatac atttatggta
6481 tgcaagcac tatcctaggt
    
```




Fig. 1. Sequence of the CXCR4 gene and promoter region. The consensus TATA box sequence and putative transcription factor consensus sites are indicated above the sequence. The two coding regions are represented in bold capital letters and the 5' UTR in italic capital letters. A schematic representation of the CXCR4 gene structure with reference to the principal hallmarks of the sequence and the restriction pattern is represented at the bottom of the figure.

2.4. Southern blotting

Ten micrograms of BAC 24D3 DNA were digested with *EcoRI*, *BamHI*, *XbaI*, *HindIII*, *SstI*, *PstI*, *XhoI*, *KpnI* and *SpeI*, run on a 0.8% agarose gel, and blotted onto a nitrocellulose membrane. A radioactive probe was synthesized by PCR amplification of a CXCR4 cDNA plasmid in the presence of 0.5 mM of $\alpha^{32}\text{P}$ -dATP and the previously described primers. This probe was hybridized to the nitrocellulose membrane. This procedure led to the identification of 3.5 and 3.7 kb bands of *BamHI* digested BAC DNA that contained the CXCR4 gene. These fragments were subcloned in pBluescript SK \pm (Stratagene) and sequenced. Further direct sequencing of the BAC clone permitted the identification of additional 1.8 kb more relative to the 5' end of the sequence characterized previously.

2.5. Primer extension

After RNA extraction from HeLa cells using the PolyATtract mRNA isolation system (Promega), CXCR4 cDNA synthesis was performed with 100 ng of $\gamma^{32}\text{P}$ -ATP end-labeled primer complementary to the coding strand of the 3' end of exon 1 (5'-GGTTCTCCAGATCGCGTGGCTACTGGAGCACTCAGGCCCT-3'). The same primer was used as sequencing primer of the genomic DNA and both products were electrophoresed in 6% polyacrylamide gel.

2.6. Construction of reporter plasmids

The larger promoter region of CXCR4 and the deletion variants were cloned from the genomic DNA by PCR into the eukaryotic expression plasmid pGEM luc (Promega). To reduce the likelihood of PCR generated mutations, all reactions were performed with Pfu DNA polymerase (Stratagene) and the amplified material was verified by sequencing. To facilitate subcloning in the expression plasmid, the primers used included the *HindIII* and the *BamHI* site at the 5' and 3' ends, respectively, for the construction smaller than 1 kb and the *BamHI* and *NotI* for constructing the 2.6 kb promoter fragment. All PCR amplifications were carried out using the antisense primer 5'-TCGAGGATCCCCAACAACTGAAGTTTCTG which encompasses the transcription start site (+1). Specific sense primers for amplification of the different promoter regions were: -2643/+1, 5'-GATCGCGGCCGCACTTAATGTTTCATAAGTATTTTC-3'; -888/+1, 5'-TCGAAAGCTTGGATCCCCACGCCTAGAAC-3'; -417/+1, 5'-TCGAAAGCTTATTGCCGCTACT-3'; -110/+1, TCGAAAGCTTCTCGCGTCTGCC-3'; -63/+1, 5'-TGGAAAGCTTAGCGGCGCATGCGC-3'; -48/+1, TCGAAAGCTTGCCTCGGAGCGTGTTTTTC-3'.

2.7. Transfection and luciferase assay

Transfections of cells were performed by electroporation. The conditions used were: 320 V and 1500 μF for PBMC; 260 V and 1500 μF for J.jhan; and 200 V, 900 μF for HeLa. Twenty-four hours upon transfection cells were stimulated for 18 h with the different stimuli. Phorbol myristate acetate (PMA, Sigma) was used at 20 ng/ml. Ionomycin (Sigma) and Phytohemagglutinin (PHA, Welcome) were used at 250 ng/ml and 1 $\mu\text{g}/\text{ml}$, respectively. Final concentrations of recombinant TNF, IL2 and synthetic SDF1 α were 5 ng/ml, 30 IU/ml and 100 nM, respectively. Stimulation with either anti-CD3 or anti-CD3+anti-CD28 antibodies were performed as described previously [16]. The luciferase activity generated in cell cultures was assessed using a commercially available kit (Boehringer Mannheim) according to the manufacturer's instructions. Results are expressed as relative light units (RLU) per milligram of protein after subtracting the background signal (lysate from non-transfected cells).

3. Results and discussion

A fragment of 8724 base pairs (bp) containing the totality of the CXCR4 coding region and 2.6 and 2.3 kb flanking sequences relative to 5' and 3', respectively, was isolated from a human genomic BAC library (the accession number in EMBL database is AJ224869). The analysis of the sequence revealed that the CXCR4 open reading frame is encoded as two exons separated by a 2.1 kb of intronic sequence. The first exon carries the sequence corresponding to the five first CXCR4 amino acids and a 5' UTR region. The second

exon codes for the last 247 amino acids and a 3' UTR sequence. The entire nucleotidic sequence corresponding to the CXCR4 ORF and flanking regions, along with a schematic representation of the CXCR4 gene, is shown in Fig. 1. Six base pairs downstream last codon of the first exon, we noted the presence of an alternative canonical splice donor site (GT). This is reminiscent of an alternative splice donor site found in the mouse CXCR4 gene which permits expression of two different transcripts [17,18]. In contrast with these results, we failed to prove that the hypothetical, alternative splicing donor site found in human CXCR4 gene we identified was efficiently used to generate two mRNA species in normal (PBMC) and transformed (J.jhan, HeLa) human cells.

To identify the promoter region boundaries, we performed a computer-assisted analysis of the sequence data. A consensus TATA box sequence was recognized 30 bp 5' upstream transcription start site (Fig. 2), suggesting that this region was the promoter of the CXCR4 gene. The CXCR4 promoter region herein described is identical to that recently described by Morihuchi et al. [19] and contains an additional and previously unidentified 5' regulatory region of 1.4 kb. The CXCR4 promoter region carries different consensus binding sites for transcriptional factors. Some of these factors are supposed to be associated with hemopoiesis or lymphocyte maturation (MAZ, C-ets2, PU.1, PEA3, Lyf1) [20–23]. Seven putative consensus binding sites for the ubiquitous SP1 sequence were also identified.

To functionally characterize the promoter region of CXCR4, a series of 5' truncations of this region were subcloned into a plasmid driving the expression of a luciferase gene. Upon transfection into different human cell types, both the constitutive and the induced expression of luciferase was measured in cytoplasmic lysates obtained from disrupted cells. Spontaneous transcriptional activity from the CXCR4 was observed from the promoter in the three cell types, J.jhan, HeLa (Fig. 3) and PBMC (Fig. 4B). In both HeLa and J.jhan cells, the maximal transcription activity corresponded to the construct carrying the longest region (-2643/+1) of the promoter. Truncation of sequences progressing from the 5' end reduced basal activity of the promoter in all three cell types. The effect was more striking in HeLa cells where removal of 5' sequences between -2643 and -888 led to a five-fold reduction of promoter activity (Fig. 3). The region spanning from -48 to +1 retained a significant level of transcriptional activity, roughly comparable to that displayed by constructs encoding upstream sequences up to position -417. This finding suggests that sequences from -48 to +1 contain the proximal element accounting for the basal activity of the promoter. We could not confirm that removal of the NRF1 consensus site for the transcription factor (-73/-62) which has been described [19] as controlling the activity of the CXCR4 minimal promoter, affected significantly the basal activity of the promoter. Differences in the type of cells used in this study might account for the divergent results.

Our findings indicate that the 1.4 kb region that we have identified and is located upstream the previously characterized promoter region [19], also contains regulatory elements involved in the control of CXCR4 constitutive transcription activity. The participation of distal regions in the control of the basal activity was more marked in epithelial cells as compared to lymphoid cells, thus suggesting some degree of tissue specificity in the regulation of the CXCR4 promoter.




Fig. 2. Identification of transcription start site of the CXCR4 mRNA by primer extension in HeLa cells. The first line represents the major CXCR4 cDNA extension product, electrophoresed in the same gel as the sequencing reaction of the genomic DNA right four lines.

The capacity of the CXCR4 promoter to undergo transactivation upon stimulation by cell activation signals was assessed using the regulatory sequences between positions –888 and +1. Among the different stimuli used, only combined addition of PMA and ionomycin proved to be an efficient signal to enhance transcription activity from the promoter in the three cell types tested (Fig. 4A and B). Thus, the capacity of different regions of the promoter to be induced and transactivated by cell activation signals was investigated by using simultaneous addition of PMA and ionomycin. We show that the promoter regions responding to cell activation differ in HeLa and J.jhan cells (Fig. 5A and B). Indeed, in HeLa cells promoter transactivation requires the presence of the more distal regions (upstream position –417). In contrast, in lymphoblastoid J.jhan cells proximal promoter elements retained significant reactivity to activation of cell signals. Thus, similar to the constitutive expression of the CXCR4 promoter, induced transcription upon cell activation may have some degree of tissue specificity that would depend on selective protein/DNA interactions.

The capacity of stimuli mimicking physiologic activation of T lymphocytes to transactivate the CXCR4 promoter, was investigated. Upon transfection with the (888/+1)-driven luciferase construct, J.jhan or HeLa cells (Fig. 4A) were treated with either TNF or SDF1 α . The transcription activity of the promoter was not modified by either stimuli despite they induced efficiently cells as indicated by I κ B α degradation (TNF) or CXCR4 endocytosis and calcium mobilization (SDF1 α) in both cell types (data not shown). Using PBMC (Fig. 4B) we also investigated the capacity of T lymphocyte mitogenic signals or IL2 to enhance transcriptional activity from the CXCR4 promoter. The constitutive activity of the promoter was not modified significantly by stimulation of PBMC with anti-CD3, anti-CD3+anti-CD28 antibodies or incubation with IL2, although these stimuli induced CD25 expression and cell proliferation (data not shown).

The constitutive expressions of the CXCR4 promoter in different cell types are in keeping with the constitutive expression of CXCR4 gene observed in human tissues [15]. CXCR4




Fig. 3. Basal activity of the 2643 bp CXCR4 promoter and different deletions in transfected HeLa and J.jhan cells. Values on top of columns are relative to these of construct (–2643/+1) which we set arbitrary as 1.




Fig. 4. Induction of the $-888/+1$ promoter region with different stimuli in HeLa and J.jhan cells (A) and healthy donor PBMC (B). The fold increases with respect to the promoter without stimulus are indicated on top of each column.

transcripts are expressed in a large diversity of tissues and transformed cell lines [14,15]. The expression of CXCR4 is also constitutive in cells of hematopoietic origin. Indeed, CXCR4 is expressed in most human resting T lymphocytes isolated from blood although the percentage of positive cells shows some degree of variability among blood donors [14,24]. CXCR4 is also expressed in most of 60% freshly isolated, human blood monocytes [24]. Interestingly in Langerhans and endothelial cells, constitutive expression of CXCR4 is detected and the protein accumulates in the cytoplasm [25,26]. Langerhans cells when kept in culture for some hours after isolation show CXCR4 at the cell membrane thus suggesting that the lack of cell surface expression could be related to microenvironmental influences [25].

However, we have not found cell signals induced by either cytokines or growth factors, or mediated through membrane receptors involved in specific T lymphocyte activation, capa-

ble to up-regulate the constitutive transcription activity of the CXCR4 promoter. Our data diverge from those of Moriuchi et al. [19] who found a discrete enhancement of CXCR4 promoter transcription activity in PBMC activated by IL2 or via CD3. Differences in the status of cell activation and differentiation might explain these divergent data. Indeed, while the experiments described by Moriuchi et al. were performed in blast T lymphocytes expanded with IL2, we transfected and induced resting PBMC. In keeping with the results published by Moriuchi et al., the enhancement of CXCR4 expression at the cell membrane in PHA-activated human T lymphocytes has been reported previously [6]. Nevertheless and in sharp contrast with these data, evidence supporting down-regulation of CXCR4 expression in PHA-stimulated T lymphocytes has been provided by Loetscher et al. [15]. Findings obtained in our laboratory confirmed Loetscher et al.'s observations and show that PHA activation induces a rapid and sustained re-




Fig. 5. Induction of CXCR4 promoter constructions by PMA and ionomycin compared with the basal level in HeLa (A) or J.ghan (B) cells. The fold increases with respect to the control without stimulus are represented over each column.

duction in the amount of CXCR4 transcripts and impair CXCR4 cell membrane expression in PBMC (Caruz and Alcamí, unpublished results). This observation could reflect either induction of a transcription inhibition mechanism or more likely a reduced stability of the CXCR4 messenger. Down-regulation of chemokine receptor after cell activation is not without precedent, and has been described previously for the chemokine receptors CCR1 and CCR2. Indeed, mitogenic activation of fully responsive lymphocytes dramatically reduced the amount of transcripts for both receptors and lead to the loss of responsiveness to RANTES and MCP-1, respectively [4]. Moreover, it has been shown recently that $\text{IFN}\gamma$, a cytokine secreted by PBMC lymphocytes in response to mitogenic stimuli [27], profoundly down-regulates CXCR4 mRNA expression in endothelial cells, a monocytoïd cell line and PBMC [28,29]. The apparently divergent findings described above should be resolved by a more detailed analysis of the

physiologic signals regulating the expression of the CXCR4 gene both at pre- and post-transcriptional phases in different cell types.

Taking into account the important role played by SDF1 in embryo development and immunological functions, on one hand, and given that CXCR4 is the only SDF1 receptor identified so far, the analysis of mechanisms regulating expression of the CXCR4 gene appears like a topic of outstanding interest for future work.

Acknowledgements: This work was supported in part by the French Agence Nationale pour la Recherche sur le SIDA, the Concerted Action of the European Union (BIOMED program, ROCIOII project) and grants SAF96/0186 y FIS 98/0337 from the Spanish government. A.C. is supported by fellowships from SIDACTION (France) and the Viral hepatitis and AIDS study group from the Virgen del Rocío Hospital (Seville, Spain). We are indebted to Dr. S. Michelson for critical reading of the manuscript.

References

- [1] Baggiolini, M., Dewald, B. and Moser, B. (1994) *Adv. Immunol.* 55, 97–179.
- [2] Murphy, P.M. (1996) *Cytokine Growth Fact. Rev.* 7, 47–64.
- [3] Rollins, B.J. (1997) *Blood* 90, 909–928.
- [4] Loetscher, P., Seitz, M., Baggiolini, M. and Moser, B. (1996) *J. Exp. Med.* 184, 569–577.
- [5] Bleul, C.C., Wu, L.J., Hoxie, J.A., Springer, T.A. and Mackay, C.R. (1997) *Proc. Natl. Acad. Sci. USA* 94, 1925–1930.
- [6] Carroll, R. et al. (1997) *Science* 276, 273–276.
- [7] Feng, Y., Broder, C.C., Kennedy, P.E. and Berger, E.A. (1996) *Science* 272, 872–877.
- [8] Oberlin, E. et al. (1996) *Nature* 382, 833–835.
- [9] Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clarklewis, I., Sodroski, J. and Springer, T.A. (1996) *Nature* 382, 829–833.
- [10] Nagasawa, T. et al. (1996) *Nature* 382, 635–638.
- [11] Aiuti, A., Webb, I.J., Bleul, C., Springer, T. and Gutierrez-Ramos, J.C. (1997) *J. Exp. Med.* 185, 111–120.
- [12] Nagasawa, T. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93, 14726–14729.
- [13] Campbell, J., Hedrick, J., Zlotnik, A., Siani, M.A., Thompson, D.A. and Butcher, E.C. (1998) *Science* 279, 381–384.
- [14] Amara, A. et al. (1997) *J. Exp. Med.* 186, 139–146.
- [15] Loetscher, M., Geiser, T., O'Reilly, T., Zwahlen, R., Baggiolini, M. and Moser, B. (1994) *J. Biol. Chem.* 9, 232–237.
- [16] Alcami, J. et al. (1995) *EMBO J.* 114, 1552–1560.
- [17] Moepps, B., Frodl, R., Rodewald, H.R., Baggiolini, M. and Gierschik, P. (1997) *Eur. J. Immunol.* 27, 2102–2112.
- [18] Heesen, M., Berman, M.A., Hopken, U.E., Gerard, N.P. and Dorf, M.E. (1997) *J. Immunol.* 158, 3561–3564.
- [19] Moriuchi, H., Moriuchi, M., Combadiere, C., Murphy, P.M. and Fauci, A.S. (1996) *Proc. Natl. Acad. Sci. USA* 93, 15341–15345.
- [20] Omori, S.A. and Wall, R. (1993) *Proc. Natl. Acad. Sci. USA* 90, 11723–11727.
- [21] Leung, E. et al. (1997) *Immunogenetics* 46, 111–119.
- [22] Wasyluk, B., S L, H. and Giovane, A. (1993) *Eur. J. Biochem.* 211, 7–18.
- [23] Bossone, S.A., Asselin, C., Patel, A.J. and Marcu, K.B. (1992) *Proc. Natl. Acad. Sci. USA* 89, 7452–7456.
- [24] Hori, T., Sakaida, H., Sato, A., Nakajima, T., Shida, H., Yoshie, O. and Uchiyama, T. (1998) *J. Immunol.* 160, 180–188.
- [25] Zaitseva, M., Blauvelt, A., Lee, S., Lapham, C.K., Klaus-Kavtun, V., Mostowski, H., Manischewitz, J. and Golding, H. (1997) *Nature Med.* 3, 1369–1375.
- [26] Volin, M.V., Joseph, L., Shockley, M.S. and Davies, P.F. (1998) *Biochem. Biophys. Res. Commun.* 242, 46–53.
- [27] Farrar, M.A. and Schreiber, R.D. (1993) *Annu. Rev. Immunol.* 11, 571–611.
- [28] Gupta, S.K., Lysko, P.G., Pillarisetti, K., Ohlstein, E. and Stadel, J.M. (1998) *J. Biol. Chem.* 273, 4282–4287.
- [29] Shirazi, Y. and Pitha, P.M. (1998) *J. Hum. Virol.* 1, 69–76.